DOCSLIB.ORG

Index to Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Index to Abstracts Index to Abstracts A Abdominal tumors, advances in diagnosis, Alcohol injections in treatment of orbital 369 (Aievoli) angiorna, 382 (Cornet) Abdominal wall (See also Umbilicus) Aleukemic leukemia. See Leukemia endometriosis of, 908 (Haselhorst) Aleukemic leukopenic chloromyelosis, 939 fibroma of, 139 (Mosto et el) (Strasser) developing at site of old trauma, 135 Aleukemic lymphadenosis associated with (Liitseler) agranulocytosis, 716 (Rittmann) Abdulla, M., 913 Aleukemic lymphomatosis of stomach in Abel, A. L., 179 child, 939 (Cibils Aguirre et al) Abel, K., 906 Alexander, 462 Abell, I., 469 Alkali reserve in blood of cancer patients, Abraham, E. G., 206 139 (Rakow) Acanthoma Alliez, J., 231 multiple branchiogenic, 394 (Lillie et al) Allott, E. N., 141 of anus, 623 (Hankins and Harding) Alvarez Cascos, 855 Acanthosis nigricans associated with gas- Ambler, J. V., 618 tric cancer, 885 (DamblB) American Society for Control of Cancer, Achard, C., 878 943 (Little) Acoustic nerve tumors (See also Brain, Amodeo, N. A., 640 cerebellopontine angle tumors) Amorosi, O., 174 surgical treatment, 231 (Balado and Ampulla of Vater. See Vater’s ampulla Morea), 700 (Dandy), 925 (Olive- Amyloid tumors of skull, radiologic diag- crona) nosis, 934 (Vogeler) Acromegaly associated with pituitary ade- Andersen, D. H., 659 noma, 230 (Stern) Anderson, H. F., 854 Adamantinoma of lower jaw, resection and Anderson, L. w., 449 artificial replacement of jaw, 159 (van Andrewes, C. H., 599 Hutten) Andrews, C. J., 683 Adenomyoma of stomach with adjacent Anemia subserosal abscess, 172 (Petrowitch and aplastic, leukemia associated with, 939 DavidoviE) (Weber and Weisswange) Adenomyosis. See Endometriosis in cancer of stomach, 168 (Mansella) Adler, J., 141 in Hodgkin’s disease, 244 (Weber) Adrenal. See Suprarenal pernicious Adson, A. W., 459, 928 associated with gastric adenoma, 172 Aerocystography, 691 (Ross) (Christoffersen) Africa, malignant melanomas in natives, coexistent with carcinoma of stomaell, 375 (Sequeira and Vint) 397 (Conner and Birkeland) Agatson, S. A., 630 specific dynamic action of food on, 240 Agranulocytosis (Kimura) aleukemic lymphadenosis associated Aneurysm, cirsoid, of splenic artery, 413 with, 716 (Rittmann) (Naegeli) leukemia and, 715 (Strumia; Ederle Angioblastoma of face following removal of and Escher) calcified cyst, 139 (Villata) Aguilar, O., 879 Angiofibrosarcoma, 848 (Barnes) Aievoli, 369, 463 Angiography, cerebral, 695 (Egas Monis) Albeaux-Fernet, 853 Angioma (See also Hemangioma, Lym- v. Albertini, A., 371 phangioma) Albot, G., 611 capillary, 367 (Ords) Albrecht, H., 198 cutaneous and intracranial, 462 (Alex- AZbright, F., 867 ander and Meyers) 948 INDEX TO VOLUME XXIII. ABSTRACTS 949 Angioma-cont. Aorta, rupture of, due to lymphatic of brain, cavernous, association with leukemia, 241 (Costa) cancer, 926 (Radovici et al) Aortography of face and mouth, 622 (Clark) in renal and pararenal tumors, 686 of iris, with glaucoma, 631 (Mawas) (doe Santos) of larynx, 393 (Russo-Frattasi) in suprarenal gland tumor, 670 (Roux- stalked cavernous, 644 (Ebskov) Berger et al) orbital, alcohol injections in, 382 Appendicitis, acute . (Cornet) caused by carcinoma of colon, 176 treatment, 622 (Gerlach) (Parker and Rosenthal) cryotherapy and diathermy, 622 with ovarian cyst, 209 (Stoian and (Durand) Costesco) Angioma racemosum of spinal meninges, Appendix 233 (Rosenhagen) carcinoids of, 178 (Hellner), 403 (St. Angiomatosis, hereditary hemorrhagic, 368 George) (Goffin and Bastenie) simulating appendicitis, 403 (Sullivan) Angiomyoma of uterus, 903 (0rs6s) carcinoma of, 178 (Vance; Rutherford), Angiosarcoma of forearm, congenital, 932 888 (Hardoiiin) (Lombard and Le Genissel) cecal polyp on occluded base of, 665 Aniline tumors of bladder, 214 (Muller), (Strauss) 449 (symposium) leiomyosarcoma of, 665 (Charache) Animal tumors, experimental. See Ex- neuromas of, 178 (Hellner) perimental tumors Arenas, N., 412, 909 Animal tumors, spontaneous Argentaffine tumors of terminal ileum, 660 compared with those of plants, 134 (Lee and Taylor) (Hamdi) Arginase in Jensen rat sarcoma, 843 in birds, 845 (Makower), 846 (Nicolai) (Edlbacher and Koller) in dog Argue, H. S., 691 contagious oral papilloma, dendritic Arm chromatophores in, 605 (Casarza) congenital angiosarcoma of, 932 (Lom- in guinea-pig, 844 (Maury) bard and Le Genissel) in horse fibrosarcoma of, at site of old trauma, 135 carcinoma of eye, 365 (Bakker) (Liitzeler) in mouse Armand-De Lille, P. F., 647, 893 effect on, of vitamins, 359 (Harde and Armstrong, M. V., 208 Koborieff) Arneth, 720 factor from normal tissues inhibit- Aron, M., 368 ing growth of, 357 (Murphy and Aronson, W., 642 Sturm) Arrhenoblastoma. See Ovary, arrhenoblas- mammary carcinoma toma of influence of hormones and vitamins Arsenic in treatment of experimental on production of, 599 (Harde) tumors, 840 (Eggers) leukemoid and leukemic conditions Arsenical (7) keratoses, multiple epitheli- associated with, 604 (Hueper) oma and, in negro boy, 376 (Hopkins therapeutic action of radium on, and Van Studdiford) 597 (Cramer) Artaud, A., 905 in rabbit, 845 (Fardeau) melanomas, action of snake venom on, Arteriography 363 (Grasset and des Ligneris) in brain tumors, 220 (Lucherini), 457 similarity of, to fasciations in plants, 837 (Bodechtel and Wichmann), 69.5 (Jones) (Hanau) Anspach, B. M., 470 in tumors of limbs, 932 (dos Santos) Anspach, W. E., 707 Qrytenoid cartilage, reaction of, to car- Antonio, C., 224 cinoma, 163 (Terracol and Guibert) Antonioli, G. M., 175 4saku1-a~T., 131 Antrum. See Sinus, maxillary 4schheim Zondek reaction, 600 (Saphir) Anus, acanthoma of, 623 (Hankina and following partial hypophysectomy, 230 Harding) (Stern) 950 INDEX TO VOLUME XXIII. ABSTR.ACTS Aschheim Zondek reaction-cont. Bargen, J. A., 665 in chorionepithelioma, 197 (Beattie), Baridty, M., 667 198 (Taketomi), 428 (Kimbrough), Barker, L. F., 709 429 (Balkow; Granzow), 907 Barlaro, P. M., 935 (Schwalm) Barnard, L., 933 of fallopian tube, 199 (Bunnag and Barnes, E. B., 848 Bachman) Barney, J. D., $42 of testis, 455 (Montpellier and Her- Barringer, B. S., 440, 448 lant) Barry, T. R., 213 retroperitoneal, in male, 894 (Fenster) Bartels, E. C., 888 in fluid from ovarian cysts, 208 (Kleine Bartholin’s gland and Paal) calcified fibroma of, 914 (Mauc ,ire) in hydatid mole and chorionepithelioma, carcinoma of, 440 (Mayo and iarber), 681 (Heim; Mann and Leff), 682 914 (Lyle) (NYSt) endometrioma of, 440 (Duncan in ovarian dermoid, 210 (Tierny) Bartstra, D. S., 654 in seminomas, 455 (BIiimeI) Basophil syndrome, 229 (Leyton) in teratoma testis, 454 (Ferguson), 693 Bastenie, P., 368, 400 (Ferguson) Bates, C. O., 932 in uterine fibroma, 196 (Kulikowska) Baumann, R., 636 Aschoff, L., 475 Baumm, H., 418 Ascites, differentiation from ovarian cyst, Beach, R. M., 197 437 (Brakemann) Beard, J. W., 841, 842 Ashby, W. R., 474 Beattie, J., 197 Astraldi, A., 450 Beaver, D. C., 407 Atheroma of scalp, basal-cell epithelioma Beck, H., 385 in, 148 (Strauss) Beck, J. C., 642 Atlee, H. B., 902 B4cZBre, A,, 837, 920 Attiah, M,A. H., 229 B4ctte, C., 188 Aubry, M., 227 Beer, A., 666 Audo-Gianotti, G. B., 224, 925 Beeson, B. B., 623 Austin, P. R., 219 Behney, C. A., 185 Auuray, 855 Behrendt, W., 648 Beilin, D. S., 883 13 Belezky, W. K., 223 Baatz, 896 Belle, 905 Babaiantz, L., 889 Bench. E. M.. 409 Babcock, J. W., 873 Bendien reaction, 141 (Patterson and Babes, A., 186 Adler; Lowe et al), 612 (Lowe) Bachman, C., 199 Benedict, W. L., 381 Bacmeister, A., 648 Benetalo, G., 603, 604 Baensch, W., 235, 378 Benetato-Modval, M., 608 Bagozzi, U. C., 640, 657 Bennett, R. J., 383 Bailey, 0. T., 451 Bennett-Jones, M. J., 372 Bais, W. J., 210 Benoit, H., 935 Bajkay, T. V., 707 Benson, F. C., 376 Bakker, B., 365 Bensidine test, 168 (Ogilvie; Taylor) Balaban, I. J.,885 Bdrarck, M., 680 Balado, M., 231 Bergendal, S., 690 Balfour, D. C., 398, 655 Berger, L.,224, 443, 856 Balkow, E., 429 Berger, R. A,, 647 Ballenger, E. G., 918 Berkeley, C., 187 Balmus, G., 720 Berlin blue colloid flocculation test, tumor Bamber, G., 154, 378 type reaction with, 142 (Buscaino) Banet, V., 862 Bernal, P., 671 Barbanti-Silva, E., 906 Bernard, 893 Barber, K. W., 440 Bernard, G. T., 896 Barbier, J., 460 Bernardbeig, J., 194, 378, 436 INDEX TO VOLUME XXIII. ABSTRACTS 95 1 Bernay, P., 658 Bladder, carcinoma, treatment-cont. Bernot, J., 209 radiotherapy and electrosurgery, Bernstein, A., 715 215 (Stevens) Bertaccini, G., 7 17 radium therapy, 212 (Silverton) Bertone, C., 413 . endometriosis of, 908 (Haselhorst) Bertrand, I., 227 myoma of, prolapsed into urethra, 692 Beutel, A,, 165 (Truc) Bezecny, R., 624 papilloma of, 450 (Joly) Biancylli, H., 882 aspiration under direct vision, 917 Bicheler, 893 (Lechnir) Biedermann, 878 recurrences of, 451 (Lorge) Bierich, R., 844 removal by suction, 451 (Hennig and Biggam, A. G., 232 Lechnir) Rile, S., 435 pressure changes in, with genital tumors Bile-duct, common and pregnancy, 672 (Eufinger) myosarcoma of, 180 (Schuppler) tumors of (See also aniline tumors of, primary carcinoma of, 409 (Lee and cancer of, etc., above) Totten) aerocystography in, 691 (Ross) Bing, M., 611 contrast roentgenography, 917 (Sal- Bingham, E. M., 454 leras) Biology of cancer, therapeutic portent of, 618 (Yates) five-year cures, 472 (Kretschmer) Biophysics and cancer, 943 (Foveau de treatment, 686 (Keyes) Courmelles) electrocoagulation, 450 (Astraldi) Biopsy, 140 (MacCarty), 611 (Von Haam), radium implantation, 450 (Keyes) 849 (Budd) two-stage operation, 691 (Crosbie) aspiration, 849 (Martin and Ellis) vesical glands
Load more

Recommended publications
  • Heart Tumors in Domestic Animals
    HEART TUMORS IN DOMESTIC ANIMALS Marko Hohšteter Department of veterinary pathology, Veterinary Faculty University of Zagreb Neoplasms of the heart are rare diseases in domestic animals. Among all domestic animals heart neoplasm are most common in dogs. Most of the canine heart tumors are primary what is contrary to other domestic animals, in which most of cardiac tumors are metastatic. Primary tumors of the heart represent 0,69% of the canine tumors. Among all primary neoplasms canine hemangiosarcoma of the right atrium is the most common. Other primary cardiac tumors in domestic animals include rhabdomyoma, rhabdomyosarcoma, myxoma, myxosarcoma, chondrosarcoma, osteosarcoma, granular cell tumor, fibroma, fibrosarcoma, lipoma, pericardial mesothelioma and undifferentiated sarcoma. Aortic and carotid body tumors are usually classified under primary heart neoplasm but are actually tumors which arise in adventitia or periarterial adipose tissue of the aorta, carotid artery or pulmonary artery, and can extend to heart base. Hemangiosarcoma is the most important and most frequent cardiac neoplasm of dogs. This tumor develops primary from the blood vessels that line the heart or can matastasize from sites such as spleen, skin or liver. It is most commonly reported in mid to large breeds, such as boxers, German shepherds, golden retrievers, and in older dogs (six years and older). Aortic and carotide body adenoma and adenocarcinoma belong into the group of chemoreceptor tumors („chemodectomas“) and are morphologicaly similar. In animals, incidence of aortic body neoplasm is higher than that of the carotide body. Both tumors mostly develop in dogs (brachyocephalic breed: boxers, Boston teriers), and are rare in cats and cattle.
    [Show full text]
  • PROPOSED REGULATION of the STATE BOARD of HEALTH LCB File No. R057-16
    PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 Section 1. Chapter 457 of NAC is hereby amended by adding thereto the following provision: 1. The Division may impose an administrative penalty of $5,000 against any person or organization who is responsible for reporting information on cancer who violates the provisions of NRS 457. 230 and 457.250. 2. The Division shall give notice in the manner set forth in NAC 439.345 before imposing any administrative penalty 3. Any person or organization upon whom the Division imposes an administrative penalty pursuant to this section may appeal the action pursuant to the procedures set forth in NAC 439.300 to 439. 395, inclusive. Section 2. NAC 457.010 is here by amended to read as follows: As used in NAC 457.010 to 457.150, inclusive, unless the context otherwise requires: 1. “Cancer” has the meaning ascribed to it in NRS 457.020. 2. “Division” means the Division of Public and Behavioral Health of the Department of Health and Human Services. 3. “Health care facility” has the meaning ascribed to it in NRS 457.020. 4. “[Malignant neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. [4] “Medical laboratory” has the meaning ascribed to it in NRS 652.060. 5. “Neoplasm” means a virulent or potentially virulent tumor, regardless of the tissue of origin. 6. “[Physician] Provider of health care” means a [physician] provider of health care licensed pursuant to chapter [630 or 633] 629.031 of NRS. 7. “Registry” means the office in which the Chief Medical Officer conducts the program for reporting information on cancer and maintains records containing that information.
    [Show full text]
  • Partners in Care – January 2017
    The newSEE CE Schedule INSIDE & on a Referralremovable Contact postcard! Info Partners In Care Veterinary Referral News from Angell Animal Medical Center Winter 2017 π Volume 11:1 π angell.org π facebook.com/AngellReferringVeterinarians PRE-HOSPITAL EYELID MARGIN SEDATION OPTIONS BUILDING A RADIOGRAPHIC TUMOR GRADING— MASSES IN DOGS: FOR AGGRESSIVE AND CONFIDENT PUPPY APPROACH TO IS IT APPLICABLE? TO CUT OR ANXIOUS DOGS BONE IMAGING NOT TO CUT? PAGE 1 PAGE 1 PAGE 4 PAGE 6 PAGE 8 ANESTHESIA BEHAVIOR Pre-Hospital Sedation Building a Options for Aggressive Confident Puppy and Anxious Dogs π Terri Bright, Ph.D., BCBA-D, CAAB π Kate Cummings, DVM, DACVAA angell.org/behavior [email protected] angell.org/anesthesia 617-989-1520 [email protected] 617-541-5048 ggressive and/or fearful dogs present several challenges for the othing makes everyone happier than having puppies in the small animal practitioner. These patients are difficult to fully veterinary office. The client brings the pup soon after they evaluate and present a safety hazard to the clinic staff, purchase or adopt it to make sure it is healthy, and to begin the veterinarian, and sometimes even the owner. In addition, a process of vaccinations and a lifetime of health. Everyone oohs Anervous dog contributes to heightened stress within the work area affecting Nand ahs over it, but what are the most important things a vet and their staff not only people, but other pets alike. In dogs known to be aggressive within can do to make sure the pup grows up to be happy and behaviorally healthy? the hospital setting or those with tremendous fear/anxiety, making physical exams and basic assessment impossible, pre-hospital sedation can First, find out what the puppy’s history is.
    [Show full text]
  • Aderomyoma of the Common Bile Duct --Report of a Case
    Yamanashl Med. J. 4 (2), 83"v87, 1989 Case Report AdeRomyoma of the Common Bile Duct --Report of a Case Yoshiro MATsuMoTe, Masatoshi MoGAKi, Hidehisa AoyAMA, Takayoshi SEKmAwA, Katsnhiko SuGAHARA, Koichi SuDAi), and Masayuki FuJiNo2) DePa,rt･ment of Surge7pu. i)DePartment of Pathology, 2)DePartment of lnte7"nal Medicine, YamanasJzi Medical Coglege, Tamaho, Nakakoma, Ya?nanashi 409-38, JaPan Abstract: Adenomyomas in the extrahepatic biie duc£ are extremely rare. In a 75-year- old male with acute cholangitis due to adenomyoma £erming a protruding lesion iR the terminal bile duct, pamacreatoduodenectomy was carried out, resulting complete cure, Key words: Adenomyoma of the common bile duct, Early bile dact cancer, Obstructive jaundice formed, aRd £rom the histologic examina- INTRODUCTION tion of the surgical specimen, adenomyoma Adenomyoma in the biliary ductal system of the common bile duct was confirmed. is most freguently fouRd in the gallbladder. Although beRign neoplasma o£ the bile The gallbiadder wall is more abuRdant in duct system are uncommon, the tumors are muscle fibers than is the wall o£ the bile clinically very important because they can duct. Adenomyoma in the gallbladder is cause obstructive jaundice4) and require knowlt to be closely re}ated to the forma- differentiation £rom eary cancer of the bile tion of gallstones. In other parts of the duct. biliary ductal system, kex4xeve]-, adeno- We report here the surgical results and myoma is very rarei)･2), although a few pathologic findings in a case of adeno- cases of a tumor arising from the papil}a myoma of the terminal bile duct. of Vater3) have beelt reported.
    [Show full text]
  • Evidenzbericht: S3-Leitlinie „Adulte Weichgewebesarkome“
    Institut für Forschung in der Operativen Medizin (IFOM) Evidenzbericht: S3-Leitlinie „Adulte Weichgewebesarkome“ IFOM - Institut für Forschung in der Operativen Medizin (Universität Witten/Herdecke) Jessica Breuing, Tim Mathes, Katharina Doni, Tanja Rombey, Barbara Prediger, Dawid Pieper Datum: 03.07.2020 Kontakt: Jessica Breuing IFOM - Institut für Forschung in der Operativen Medizin Univ.-Prof. Dr. Rolf Lefering Fakultät für Gesundheit, Department für Humanmedizin Universität Witten/Herdecke Ostmerheimer Str. 200, Haus 38 51109 Köln Tel.: 0221 98957-41 Fax: 0221 98957-30 Dr. Tim Mathes IFOM - Institut für Forschung in der Operativen Medizin Univ.-Prof. Dr. Rolf Lefering Fakultät für Gesundheit, Department für Humanmedizin Universität Witten/Herdecke Ostmerheimer Str. 200, Haus 38 51109 Köln Tel.: 0221 98957-43 Fax: 0221 98957-30 Inhalt 1. Literaturrecherche ........................................................................................................................ 5 1.1. Einschlusskriterien Systemtherapie ....................................................................................... 5 1.1.1. Neoadjuvante Systemtherapie (+ GIST) ........................................................................ 5 1.1.2. Adjuvante Systemtherapie (+ GIST) ............................................................................... 5 1.1.3. Therapie der metastasierten Erkrankung (+ GIST) ...................................................... 6 1.2. Einschlusskriterien Chirurgie ..................................................................................................
    [Show full text]
  • HIV-1: Cancer Evaluation 8/1/16
    Report on Carcinogens Monograph on Human Immunodeficiency Virus Type 1 August 2016 Report on Carcinogens Monograph on Human Immunodeficiency Virus Type 1 August 1, 2016 Office of the Report on Carcinogens Division of the National Toxicology Program National Institute of Environmental Health Sciences U.S. Department of Health and Human Services This Page Intentionally Left Blank RoC Monograph on HIV-1: Cancer Evaluation 8/1/16 Foreword The National Toxicology Program (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headquartered at the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS/NIH). Three agencies contribute resources to the program: NIEHS/NIH, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention (NIOSH/CDC), and the National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA). Established in 1978, the NTP is charged with coordinating toxicological testing activities, strengthening the science base in toxicology, developing and validating improved testing methods, and providing information about potentially toxic substances to health regulatory and research agencies, scientific and medical communities, and the public. The Report on Carcinogens (RoC) is prepared in response to Section 301 of the Public Health Service Act as amended. The RoC contains a list of identified substances (i) that either are known to be human carcinogens or are reasonably anticipated to be human carcinogens and (ii) to which a significant number of persons residing in the United States are exposed. The NTP, with assistance from other Federal health and regulatory agencies and nongovernmental institutions, prepares the report for the Secretary, Department of HHS.
    [Show full text]
  • SNOMED CT Codes for Gynaecological Neoplasms
    SNOMED CT codes for gynaecological neoplasms Authors: Brian Rous1 and Naveena Singh2 1Cambridge University Hospitals NHS Trust and 2Barts Health NHS Trusts Background (summarised from NHS Digital): • SNOMED CT is a structured clinical vocabulary for use in an electronic health record. It forms an integral part of the electronic care record, and serves to represent care information in a clear, consistent, and comprehensive manner. • The move to a single terminology, SNOMED CT, for the direct management of care of an individual, across all care settings in England, is recommended by the National Information Board (NIB), in “Personalised Health and Care 2020: A Framework for Action”. • SNOMED CT is owned, managed and licensed by SNOMED International. NHS Digital is the UK Member's National Release Centre for the creation of, and delegated authority to licence the SNOMED CT Edition and derivatives. • The benefits of using SNOMED CT in electronic care records are that it: • enables sharing of vital information consistently within and across health and care settings • allows comprehensive coverage and greater depth of details and content for all clinical specialities and professionals • includes diagnosis and procedures, symptoms, family history, allergies, assessment tools, observations, devices • supports clinical decision making • facilitates analysis to support clinical audit and research • reduces risk of misinterpretations of the record in different care settings • Implementation plans for England: • SNOMED CT must be implemented across primary care and deployed to GP practices in a phased approach from April 2018. • Secondary care, acute care, mental health, community systems, dentistry and other systems used in direct patient care must use SNOMED CT as the clinical terminology, before 1 April 2020.
    [Show full text]
  • Polypoid Adenomyoma of the Uterus
    Open Access Case Report DOI: 10.7759/cureus.4044 Polypoid Adenomyoma of the Uterus Nida Sajjad 1 , Hina Iqbal 1 , Kumail Khandwala 1 , Shaista Afzal 1 1. Radiology, Aga Khan University Hospital, Karachi, PAK Corresponding author: Kumail Khandwala, [email protected] Abstract Polypoid adenomyoma is a rare uterine endometrial polypoid tumor of mixed epithelial and mesenchymal origin. Although the clinical and pathologic features of polypoid adenomyomas have been described extensively, imaging findings for these tumors have not been frequently reported in the literature. On imaging, their features may be confused with prolapsed leiomyomas or malignancy. Hemorrhagic cystic spaces in a prolapsed uterine tumor within the vagina should raise consideration of a diagnosis of polypoid adenomyoma. Such blood-containing cystic spaces would be unusual findings in leiomyomas and malignancy. Diagnosing polypoid adenomyoma is vital because it can potentially be managed by hysteroscopic resection, unlike an ordinary form of adenomyosis. Categories: Obstetrics/Gynecology, Radiology Keywords: mesenchymal tumor, atypical polypoid adenomyoma, uterus Introduction Polypoid adenomyoma of the uterus is an endometrial polyp in which the stromal component is made up of smooth muscle [1]. These are benign tumors and account for 1.3% of all endometrial polyps. Polypoid adenomyomas are of mixed epithelial and mesenchymal origin [2]. Although their clinical and pathological features have been described well in literature, imaging findings for these tumors have been seldom reported. We report a case of a 44-year-old woman with urinary retention who had a prolapsed polypoidal uterine lesion on imaging which was confirmed to be polypoid adenomyoma on histopathology. We aim to review the imaging findings and the relevant literature on this rare entity.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Bone and Soft Tissue Sarcomas
    Bone and Soft Tissue Sarcomas Changes to Pathology Codes in the 4th Edition of the World Health Organisation Classification of Bone and Soft Tissue Sarcomas September 2013 Page 1 of 17 Authors Mr Matthew Francis Cancer Analysis Development Manager, Public Health England Knowledge & Intelligence Team (West Midlands) Dr Nicola Dennis Sarcoma Analyst, Public Health England Knowledge & Intelligence Team (West Midlands) Ms Jackie Charman Cancer Data Development Analyst Public Health England Knowledge & Intelligence Team (West Midlands) Dr Gill Lawrence Breast and Sarcoma Cancer Analysis Specialist, Public Health England Knowledge & Intelligence Team (West Midlands) Professor Rob Grimer Consultant Orthopaedic Oncologist The Royal Orthopaedic Hospital NHS Foundation Trust For any enquiries regarding the information in this report please contact: Mr Matthew Francis Public Health England Knowledge & Intelligence Team (West Midlands) Public Health Building The University of Birmingham Birmingham B15 2TT Tel: 0121 414 7717 Fax: 0121 414 7712 E-mail: [email protected] Acknowledgements The Public Health England Knowledge & Intelligence Team (West Midlands) would like to thank the following people for their valuable contributions to this report: Dr Chas Mangham Consultant Orthopaedic Pathologist, Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust Professor Nick Athanasou Professor of Musculoskeletal Pathology, University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences Copyright @ PHE Knowledge & Intelligence Team (West Midlands) 2013 1.0 EXECUTIVE SUMMARY Page 2 of 17 The 4th edition of the World Health Organisation (WHO) Classification of Tumours of Soft Tissue and Bone which was published in 2012 contains notable changes from the 2002 3rd edition. The key differences between the 3rd and 4th editions can be seen in Table 1.
    [Show full text]
  • Canine Myxosarcomas, a Retrospective Analysis of 32 Dogs (2003–2018) Yoshimi Iwaki1* , Stephanie Lindley1, Annette Smith1, Kaitlin M
    Iwaki et al. BMC Veterinary Research (2019) 15:217 https://doi.org/10.1186/s12917-019-1956-z RESEARCH ARTICLE Open Access Canine myxosarcomas, a retrospective analysis of 32 dogs (2003–2018) Yoshimi Iwaki1* , Stephanie Lindley1, Annette Smith1, Kaitlin M. Curran2 and Jayme Looper3 Abstract Background: Myxosarcomas are known to be classified as soft tissue sarcomas. However, there is limited clinical characterization pertaining specifically to canine cutaneous myxosarcomas in the literature. The objective of this study is to evaluate the local recurrence rate, metastatic rate and prognosis of canine myxosarcoma. Results: A total of 32 dogs diagnosed with myxosarcoma via histopathology were included in this retrospective study. All dogs had surgical resection. No adjunct treatments were performed in 9 dogs, while 22 dogs also received either radiation therapy or chemotherapy, or a combination of both. One dog received only NSAID after surgery. Overall median survival time (MST) was 730 days (range 20–2345 days). The MST of dogs with a tumor mitotic count < 10/10 HPF was 1393 days (range 20–2345 days). The dogs with a tumor mitotic count of 10 or greater/10 HPF had a MST of 433 days (range 169–831 days). There was no significant difference of MST among different treatment modalities. Local recurrence was noted in 13 cases (40.6%) and the median time to recurrence was 115.5 days (range 50–1610 days). The median time to local recurrence in dogs with mitotic count of < 10/10 HPF was 339 days (range 68–1610 days) and in dogs with mitotic count of 10 or greater/10 HPF was 119 days (range 50–378).
    [Show full text]
  • Ultra-Rare Cystic Disease
    SERIES ULTRA-RARE LUNG DISEASE Ultra-rare cystic disease Davide Elia1, Olga Torre1, Roberto Cassandro1, Antonella Caminati1 and Sergio Harari 1,2,3 Number 2 in the Series “Ultra-rare lung disease” Edited by Sergio Harari and Marc Humbert Affiliations: 1U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria - Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe - MultiMedica IRCCS, Milan, Italy. 2Dept of Medical Sciences San Giuseppe Hospital MultiMedica IRCCS, Milan, Italy. 3Dept of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Correspondence: Roberto Cassandro. U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria - Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe - MultiMedica IRCCS, Via San Vittore 12, 20123 Milan, Italy. E-mail: [email protected] @ERSpublications Diffuse cystic lung diseases show a characteristic CT scan pattern that often allows for diagnosis, even in asymptomatic patients, allowing prompt correct therapy and management without the needing of a biopsy https://bit.ly/2wIUKet Cite this article as: Elia D, Torre O, Cassandro R, et al. Ultra-rare cystic disease. Eur Respir Rev 2020; 29: 190163 [https://doi.org/10.1183/16000617.0163-2019]. ABSTRACT Diffuse cystic lung diseases include a group of heterogeneous disorders characterised by the presence of cysts within the lung parenchyma, sometimes showing a characteristic computed tomography scan pattern that allows diagnosis. The pathogenetic mechanisms underlying cyst formation in the lung are still not clear and a number of hypotheses have been postulated according to the different aetiologies: ball-valve effect, ischaemic dilatation of small airways and alveoli related to infiltration and obstruction of small vessels and capillaries that supply the terminal bronchioles and connective tissue degradation by matrix metalloproteases.
    [Show full text]